PolyPeptide Group AG Logo

PolyPeptide Group AG

PPGN | SW

Overview

Corporate Details

ISIN(s):
CH1110760852
LEI:
5067007JCKTPOX4G9758
Country:
Switzerland
Address:
Neuhofstrasse 24, 6340 Baar
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPeptide Group AG is a global Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company provides comprehensive services to pharmaceutical and biotech partners, supporting the development and manufacturing of both proprietary and generic products. PolyPeptide assists clients throughout the product lifecycle, from initial development to regulatory approval and commercial launch. A key focus is on innovation in large-scale production and sustainable manufacturing processes, such as green peptide chemistry, to enhance process performance while minimizing environmental impact.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PolyPeptide Group AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-12 06:55
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 31.7 KB
2025-08-12 02:00
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 28.4 KB
2025-08-12 02:00
Earnings Release
PolyPeptide wächst im ersten Halbjahr 2025 um 24%, mit einer erfolgreichen Anla…
German 32.6 KB
2025-05-23 07:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 7.8 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 6.0 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide gibt Ausweitung des bestehenden Kreditrahmens bekannt
German 7.0 KB
2025-04-09 18:34
Post-Annual General Meeting Information
PolyPeptide announces results of the annual General Meeting 2025
English 9.3 KB
2025-03-19 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 7.1 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025
German 8.0 KB
2025-03-12 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB
2025-03-11 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB
2025-03-11 01:00
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 28.2 KB
2025-03-11 01:00
Earnings Release
PolyPeptide mit substantiellen Verbesserungen bei Profitabilität und Cashflow, …
German 32.0 KB

Automate Your Workflow. Get a real-time feed of all PolyPeptide Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PolyPeptide Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-09 N/A Non-Executive member Buy None 75,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 72,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 75,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 72,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 35,000.00 CHF
2023-11-10 N/A Executive member Buy None 51,250.00 CHF
2023-10-11 N/A Executive member Buy None 2,876,348.62 CHF
2023-10-10 N/A Executive member Buy None 371,202.96 CHF

Peer Companies

Company Country Ticker View
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celon Pharma S.A. Logo
An integrated biopharma company developing drugs for neurology and cancer, from R&D to market.
Poland CLN
Chemical Works of Gedeon Richter Plc Logo
Develops and markets drugs for women's health, CNS, and cardiovascular conditions worldwide.
Hungary RICHT
Chiome Bioscience Inc. Logo Japan 4583
Chordia Therapeutics,Inc Logo Japan 190A
CHUGAI PHARMACEUTICAL CO., LTD. Logo Japan 4519
CHUKYOIYAKUHIN CO.,LTD. Logo Japan 4558
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS